186 related articles for article (PubMed ID: 24339928)
1. BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia.
Leo E; Mancini M; Aluigi M; Luatti S; Castagnetti F; Testoni N; Soverini S; Santucci MA; Martinelli G
PLoS One; 2013; 8(12):e81425. PubMed ID: 24339928
[TBL] [Abstract][Full Text] [Related]
2. DNA methyltransferase 1 drives transcriptional down-modulation of β catenin antagonist Chibby1 associated with the BCR-ABL1 gene of chronic myeloid leukemia.
Leo E; Mancini M; Castagnetti F; Gugliotta G; Santucci MA; Martinelli G
J Cell Biochem; 2015 Apr; 116(4):589-97. PubMed ID: 25389112
[TBL] [Abstract][Full Text] [Related]
3. A calpain-cleaved fragment of β-catenin promotes BCRABL1+ cell survival evoked by autophagy induction in response to imatinib.
Mancini M; Leo E; Campi V; Castagnetti F; Zazzeroni L; Gugliotta G; Santucci MA; Martinelli G
Cell Signal; 2014 Aug; 26(8):1690-7. PubMed ID: 24747551
[TBL] [Abstract][Full Text] [Related]
4. Chibby 1: a new component of β-catenin-signaling in chronic myeloid leukemia.
Mancini M; Soverini S; Gugliotta G; Santucci MA; Rosti G; Cavo M; Martinelli G; Castagnetti F
Oncotarget; 2017 Oct; 8(50):88244-88250. PubMed ID: 29152155
[TBL] [Abstract][Full Text] [Related]
5. 14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia.
Mancini M; Leo E; Takemaru K; Campi V; Castagnetti F; Soverini S; De Benedittis C; Rosti G; Cavo M; Santucci MA; Martinelli G
PLoS One; 2015; 10(7):e0131074. PubMed ID: 26147002
[TBL] [Abstract][Full Text] [Related]
6. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
Reddiconto G; Toto C; Palamà I; De Leo S; de Luca E; De Matteis S; Dini L; Passerini CG; Di Renzo N; Maffia M; Coluccia AM
Blood; 2012 Mar; 119(10):2335-45. PubMed ID: 22262776
[TBL] [Abstract][Full Text] [Related]
7. Chibby drives β catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells.
Mancini M; Leo E; Takemaru K; Campi V; Borsi E; Castagnetti F; Gugliotta G; Santucci MA; Martinelli G
Cell Signal; 2013 Sep; 25(9):1820-7. PubMed ID: 23707389
[TBL] [Abstract][Full Text] [Related]
8. Regulative Loop between β-catenin and Protein Tyrosine Receptor Type γ in Chronic Myeloid Leukemia.
Tomasello L; Vezzalini M; Boni C; Bonifacio M; Scaffidi L; Yassin M; Al-Dewik N; Takam Kamga P; Krampera M; Sorio C
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32225105
[TBL] [Abstract][Full Text] [Related]
9. Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors.
Mancini M; De Santis S; Monaldi C; Bavaro L; Martelli M; Castagnetti F; Gugliotta G; Rosti G; Santucci MA; Martinelli G; Cavo M; Soverini S
J Exp Clin Cancer Res; 2019 May; 38(1):216. PubMed ID: 31122263
[TBL] [Abstract][Full Text] [Related]
10. FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage.
Mancini M; Castagnetti F; Soverini S; Leo E; De Benedittis C; Gugliotta G; Rosti G; Bavaro L; De Santis S; Monaldi C; Martelli M; Santucci MA; Cavo M; Martinelli G
J Cell Biochem; 2017 Nov; 118(11):3968-3975. PubMed ID: 28401599
[TBL] [Abstract][Full Text] [Related]
11. Tetrandrine citrate eliminates imatinib-resistant chronic myeloid leukemia cells in vitro and in vivo by inhibiting Bcr-Abl/β-catenin axis.
Xu XH; Gan YC; Xu GB; Chen T; Zhou H; Tang JF; Gu Y; Xu F; Xie YY; Zhao XY; Xu RZ
J Zhejiang Univ Sci B; 2012 Nov; 13(11):867-74. PubMed ID: 23125079
[TBL] [Abstract][Full Text] [Related]
12. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.
Neviani P; Harb JG; Oaks JJ; Santhanam R; Walker CJ; Ellis JJ; Ferenchak G; Dorrance AM; Paisie CA; Eiring AM; Ma Y; Mao HC; Zhang B; Wunderlich M; May PC; Sun C; Saddoughi SA; Bielawski J; Blum W; Klisovic RB; Solt JA; Byrd JC; Volinia S; Cortes J; Huettner CS; Koschmieder S; Holyoake TL; Devine S; Caligiuri MA; Croce CM; Garzon R; Ogretmen B; Arlinghaus RB; Chen CS; Bittman R; Hokland P; Roy DC; Milojkovic D; Apperley J; Goldman JM; Reid A; Mulloy JC; Bhatia R; Marcucci G; Perrotti D
J Clin Invest; 2013 Oct; 123(10):4144-57. PubMed ID: 23999433
[TBL] [Abstract][Full Text] [Related]
13. Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.
Manachai N; Saito Y; Nakahata S; Bahirvani AG; Osato M; Morishita K
Biochem Biophys Res Commun; 2017 Jan; 482(4):994-1000. PubMed ID: 27908728
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profile of circulating CD34(+) cells and granulocytes in chronic myeloid leukemia.
Čokić VP; Mojsilović S; Jauković A; Kraguljac-Kurtović N; Mojsilović S; Šefer D; Mitrović Ajtić O; Milošević V; Bogdanović A; Đikić D; Milenković P; Puri RK
Blood Cells Mol Dis; 2015 Dec; 55(4):373-81. PubMed ID: 26460262
[TBL] [Abstract][Full Text] [Related]
15. Ubiquitin-mediated interaction of p210 BCR/ABL with β-catenin supports disease progression in a murine model for chronic myelogenous leukemia.
Chen R; Hu T; Mahon GM; Tala I; Pannucci NL; Ozer HL; Whitehead IP
Blood; 2013 Sep; 122(12):2114-24. PubMed ID: 23950177
[TBL] [Abstract][Full Text] [Related]
16. KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.
Corbin AS; O'Hare T; Gu Z; Kraft IL; Eiring AM; Khorashad JS; Pomicter AD; Zhang TY; Eide CA; Manley PW; Cortes JE; Druker BJ; Deininger MW
Cancer Res; 2013 Sep; 73(18):5775-86. PubMed ID: 23887971
[TBL] [Abstract][Full Text] [Related]
17. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
Aljedai A; Buckle AM; Hiwarkar P; Syed F
PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
[TBL] [Abstract][Full Text] [Related]
18. Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.
Gleixner KV; Schneeweiss M; Eisenwort G; Berger D; Herrmann H; Blatt K; Greiner G; Byrgazov K; Hoermann G; Konopleva M; Waliul I; Cumaraswamy AA; Gunning PT; Maeda H; Moriggl R; Deininger M; Lion T; Andreeff M; Valent P
Haematologica; 2017 Sep; 102(9):1519-1529. PubMed ID: 28596283
[TBL] [Abstract][Full Text] [Related]
19. Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.
Mukherjee K; Sha X; Magimaidas A; Maifrede S; Skorski T; Bhatia R; Hoffman B; Liebermann DA
Oncotarget; 2017 Feb; 8(7):10809-10821. PubMed ID: 28086219
[TBL] [Abstract][Full Text] [Related]
20. RAG enhances BCR-ABL1-positive leukemic cell growth through its endonuclease activity in vitro and in vivo.
Yuan M; Wang Y; Qin M; Zhao X; Chen X; Li D; Miao Y; Otieno Odhiambo W; Liu H; Ma Y; Ji Y
Cancer Sci; 2021 Jul; 112(7):2679-2691. PubMed ID: 33949040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
